跨膜蛋白33在肿瘤发生发展中的作用

doi:10.16352/j.issn.1001-6325.2025.02.0258

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (2): 258-262.doi: 10.16352/j.issn.1001-6325.2025.02.0258

跨膜蛋白33在肿瘤发生发展中的作用

楼海均¹, 孟·孟根², 张振宇¹, 童卓云¹, 乌都木丽^1*

新疆医科大学 1.基础医学院病理教研室;
2.第五临床医学院检验科,新疆乌鲁木齐 830017

收稿日期:2024-02-20 修回日期:2024-07-05 出版日期:2025-02-05 发布日期:2025-01-17
通讯作者: ^*wudumuli@xjmu.edu.cn
基金资助:
新疆维吾尔自治区青年自然科学基金(2020D01C175);新疆维吾尔自治区重点研发计划(2022B03019-1-1)

Role of transmembrane protein 33 in tumorigenesis and development

LOU Haijun¹, MENG Menggen², ZHANG Zhenyu¹, TONG Zhuoyun¹, WUDU Muli^{1 *}

1. Department of Pathology, School of Basic Medicine;
2. Department of Clinical Laboratory, the Fifth Clinical College of Medicine, Xinjiang Medical University, Urumqi 830017,China

Received:2024-02-20 Revised:2024-07-05 Online:2025-02-05 Published:2025-01-17
Contact: ^*wudumuli@xjmu.edu.cn

摘要/Abstract

摘要： 跨膜蛋白33(transmembrane protein 33,TMEM33)在大多数癌中表达上调。改变TMEM33表达可以显著影响肾癌和宫颈癌细胞的增殖、迁移和侵袭。其作用机制可能有4个方面:1)参与脂质代谢; 2)调节内质网应激; 3)参与调节细胞内钙稳态; 4)参与血管生成。

关键词: 跨膜蛋白33, 肿瘤发展, 肿瘤转移, 生物标志物, 治疗靶点

Abstract: Transmembrane protein 33 (TMEM33) is up-regulated in the majority of cancers. To change the expression of TMEM33 can significantly affect the proliferation, migration, and invasion of renal and cervical cancer cells. Its mechanisms of action may involve four aspects: 1)participation in lipid metabolism; 2)regulation of endoplasmic reticulum; 3)regulation of intracellular calcium homeostasis; 4) participation in angiogenesis.

Key words: transmembrane protein 33, tumor development, tumor metastasis, biomarker, therapeutic target

中图分类号:

R363.1

楼海均, 孟·孟根, 张振宇, 童卓云, 乌都木丽. 跨膜蛋白33在肿瘤发生发展中的作用[J]. 基础医学与临床, 2025, 45(2): 258-262.

LOU Haijun, MENG Menggen, ZHANG Zhenyu, TONG Zhuoyun, WUDU Muli. Role of transmembrane protein 33 in tumorigenesis and development[J]. Basic & Clinical Medicine, 2025, 45(2): 258-262.

参考文献 17

[1]	董晶, 商双, 高蜀君, 等. RNA干扰 TMEM33 的表达对宫颈癌细胞生长的影响[J].复旦学报(医学版),2023,50: 159-165.
[2]	Zhang J, Lu Q, Pang H, et al. miR-103a-3p aggravates renal cell carcinoma by targeting TMEM33[J]. Am J Transl Res, 2021,13: 12694-12703.
[3]	Huang Z, Li J, Du S, et al. Fkbp14 overexpression contributes to osteosarcoma carcinogenesis and indicates poor survival outcome[J]. Oncotarget, 2016, 7: 39872-39884.
[4]	Venkataramani V, Yang Y, Schubert MC, et al. Glioblastoma hijacks neuronal mechanisms for brain invasion[J]. Cell, 2022, 185: 2899-2917.
[5]	Liu F, Ma M, Gao A, et al. PKM2-TMEM33 axis regulates lipid homeostasis in cancer cells by controlling scap stability[J]. EMBO J, 2021, 40: e108065. doi:10.15252/embj.2021108065.
[6]	Perez CM, Felty Q. Molecular basis of the association between transcription regulators nuclear respiratory factor 1 and inhibitor of DNA binding protein 3 and the development of microvascular lesions[J]. Microvasc Res, 2022, 141: 104337. doi:10.1016/j.mvr.2022.104337.
[7]	Suliman HB, Healy Z, Zobi F, et al. Nuclear respiratory factor-1 negatively regulates TGF-β1 and attenuates pulmonary fibrosis[J]. iScience, 2022, 25: 103535. doi:10.1016/j.isci.2021.103535.
[8]	Li H, Niu N, Yang J, et al. Nuclear respiratory factor 1 protects H9c2 cells against hypoxia-induced apoptosis via the death receptor pathway and mitochondrial pathway[J]. Cell Biol Int, 2021, 45: 1784-1796.
[9]	Sakabe I, Hu R, Jin L, et al. TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling[J]. Breast Cancer Res Treat, 2015, 153: 285-297.
[10]	Chao X, Wang S, Fulte S, et al. Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mtorc1 activation and defective autophagy[J]. J Hepatol, 2022, 76: 639-651.
[11]	Tao M, Liu T, You Q, et al. P62 as a therapeutic target for tumor[J].Eur J Med Chem. 2020;193:112231. doi:10.1016/j.ejmech.2020.112231.
[12]	Zhang X, Dai M, Li S, et al. The emerging potential role of p62 in cancer treatment by regulating metabolism[J]. Trends Endocrinol Metab, 2023, 34: 474-488.
[13]	Nowak KL, Hopp K. Metabolic reprogramming in auto-somal dominant polycystic kidney disease: evidence and therapeutic potential[J]. Clin J Am Soc Nephrol, 2020, 15: 577-584.
[14]	Ghalehbandi S, Yuzugulen J, Pranjol MZI, et al. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF[J]. Eur J Pharmacol, 2023, 949: 175586.doi: 10.1016/j.ejphar.2023.175586.
[15]	Lu LF, Zhang C, Li ZC, et al. A novel role of zebrafish tmem33 in negative regulation of interferon production by two distinct mechanisms[J]. PLoS Pathog, 2021, 17: e1009317. doi:10.1371/journal.ppat.1009317.
[16]	Zhang D, Vjestica A, Oliferenko S. The cortical ER network limits the permissive zone for actomyosin ring assembly[J]. Curr Biol, 2010, 20: 1029-1034.
[17]	Tsai PL, Cameron CJF, Forni MF, et al. Dynamic quality control machinery that operates across compartmental borders mediates the degradation of mammalian nuclear membrane proteins[J]. Cell Rep, 2022, 41: 111675. doi:10.1016/j.celrep.2022.111675.

编辑推荐 0

Metrics

阅读次数

全文

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	15

	来源	本网站

	次数	15
	比例	100%

摘要

最新录用	在线预览	正式出版

0	0	58

	来源	本网站

	次数	58
	比例	100%

跨膜蛋白33在肿瘤发生发展中的作用

Role of transmembrane protein 33 in tumorigenesis and development

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 17

相关文章 15

编辑推荐 0

Metrics

本文评价

[1]	李运龙, 李蕊, 张玉萍, 王瑞, 刘燕萍. 孕期锌缺乏及对妊娠结局的影响[J]. 基础医学与临床, 2024, 44(4): 422-427.
[2]	曹罗元, 董文婿, 杨菁, 郭立文, 陆娇娇, 郑娴, 富显果. miR-124-3p在β-地中海贫血中的差异表达及临床意义[J]. 基础医学与临床, 2024, 44(12): 1633-1637.
[3]	王继辉, 曹吉烈, 张立军, 张军, 鹿文葆. TARBP2降解AKAP12转录本促进人乳腺癌细胞转移[J]. 基础医学与临床, 2023, 43(8): 1259-1264.
[4]	郑行健, 冉雪, 任梓月, 戴迟兵. 肠易激综合征生物标志物的研究进展[J]. 基础医学与临床, 2023, 43(3): 500-504.
[5]	徐倩, 段华, 甘露, 刘麒薇. RhoGTP酶活化蛋白在上皮细胞间质转化中作用的研究进展[J]. 基础医学与临床, 2023, 43(2): 301-305.
[6]	姚刘旭, 李玉红, 蒋宗明. 外泌体lncRNA在结直肠癌液体活检中的研究进展[J]. 基础医学与临床, 2023, 43(2): 317-321.
[7]	谢思安, 陈奕阳, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 张澍田. PTOV1表达水平对结直肠癌患者预后的影响[J]. 基础医学与临床, 2022, 42(8): 1176-1181.
[8]	谢思安, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 刘思. VAV1是动脉粥样硬化预后的潜在靶点和生物标志物[J]. 基础医学与临床, 2022, 42(7): 1092-1098.
[9]	何丹, 阮中宝. 细胞外囊泡在心房颤动发病中的作用[J]. 基础医学与临床, 2022, 42(4): 671-674.
[10]	谢聪聪, 王雪莹, 安卓, 姚胜杰, 马婧, 王树松. 胚胎发育生物标志物的研究进展[J]. 基础医学与临床, 2022, 42(1): 168-172.
[11]	李英杰, 杨庭楷, 纪志刚, 文进. 外泌体在前列腺癌诊疗中的研究进展[J]. 基础医学与临床, 2022, 42(1): 163-167.
[12]	郑亚男, 李梅, 赵基源. 乳腺癌骨转移分子机制及靶向药物的研究进展[J]. 基础医学与临床, 2021, 41(3): 433-437.
[13]	周嘉怡, 吴逊伟, 戴莉娟, 赵瑰丽, 余波澜. 子痫前期孕妇外周血游离DNA的研究进展[J]. 基础医学与临床, 2020, 40(12): 1701-1705.
[14]	叶君, 刘丹瑜, 何权, 黄凤鸣, 朱华栋, 徐军, 蒋澄宇. hsa-miR-10a-5p在重症社区获得性肺炎中的应用研究[J]. 基础医学与临床, 2020, 40(10): 1313-1319.
[15]	杨丽君郭正光景宗攀孙玉琳孙伟赵晓航. 室温放置4 h对样本尿蛋白质组分析的影响[J]. 基础医学与临床, 2019, 39(9): 1330-1334.